Robert W. Baird upgraded shares of Illumina, Inc. (NASDAQ:ILMN) from a neutral rating to an outperform rating in a research note published on Wednesday, October 25th, Marketbeat reports. The brokerage currently has $228.00 target price on the life sciences company’s stock, up from their prior target price of $184.00.
Several other research analysts have also weighed in on the stock. Leerink Swann reiterated an outperform rating and set a $225.00 price objective (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies reissued an overweight rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a research report on Monday, October 9th. Vetr raised shares of Illumina from a buy rating to a strong-buy rating and set a $197.84 target price for the company in a research report on Monday, July 3rd. Morgan Stanley reissued an underweight rating and set a $122.00 target price (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Finally, Janney Montgomery Scott raised shares of Illumina from a sell rating to a neutral rating in a research report on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $200.88.
Illumina (NASDAQ:ILMN) opened at $208.94 on Wednesday. The stock has a market cap of $30,510.00, a PE ratio of 61.09, a price-to-earnings-growth ratio of 3.45 and a beta of 0.74. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a 1-year low of $119.37 and a 1-year high of $214.50.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 21.29% and a return on equity of 23.48%. The firm’s quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 EPS. equities research analysts predict that Illumina will post 3.75 earnings per share for the current year.
In other Illumina news, SVP Oene Mark Van sold 9,729 shares of Illumina stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the transaction, the senior vice president now owns 24,908 shares of the company’s stock, valued at approximately $5,263,807.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $210.59, for a total value of $4,211,800.00. Following the transaction, the director now directly owns 536,717 shares in the company, valued at approximately $113,027,233.03. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 187,964 shares of company stock worth $38,454,069. 1.60% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC lifted its holdings in Illumina by 60.7% in the 1st quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock worth $65,577,000 after purchasing an additional 145,231 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Illumina by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 264,925 shares of the life sciences company’s stock worth $45,211,000 after purchasing an additional 9,017 shares during the last quarter. KCG Holdings Inc. acquired a new stake in Illumina in the 1st quarter worth approximately $290,000. AQR Capital Management LLC increased its position in Illumina by 58.9% in the 1st quarter. AQR Capital Management LLC now owns 109,234 shares of the life sciences company’s stock worth $18,640,000 after buying an additional 40,477 shares during the period. Finally, Tudor Investment Corp ET AL bought a new position in Illumina in the 1st quarter worth approximately $289,000. Institutional investors and hedge funds own 93.07% of the company’s stock.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.